Topical Application of Wogonin Provides a Novel Treatment of Knee Osteoarthritis

Abstract

Osteoarthritis (OA) is a degenerative joint disease characterized by joint pain, decreased functional mobility, and deformation of articular cartilage and consequentially diminishing quality of life. Wogonin (WG), a compound extracted from the Skullcap Baicalensis plant, has been shown to have anti‐inflammatory effects on the Toll‐like Receptor 4 (TLR‐4) inflammatory pathway and antioxidant properties via Nrf2. We have shown that TLR‐4 is a major receptor for pain in OA. In our study, we examined the pain reducing, anti‐inflammatory, and chondroprotective effects of WG when applied as a topical cream (TC). After destabilizing the menisci of mice to induce OA, we examined the severity and progression of OA with and without the topical application of WG. Using a running wheel to track mice activity, we found that mice with WG treatment were statistically more active than mice without WG treatment. OA progression analyzed using Modified Mankin and OARSI scoring showed a significant attenuation of OA severity among mice treated with WG. Immunohistochemistry revealed a significant decrease in protein expression of TGF‐β1, but no significant differences were found among the biomarkers HTRA1, MMP‐13, or BMP‐2, suggesting an alternative pathway of cartilage rescue.Support or Funding InformationBYU Office of Research and Creative WorksThis abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.